close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

24.45 -0.10 (-0.41%)
Streaming Delayed Price Updated: 3:56 PM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Two Big Weeks To Play A Rally In Biotech And Healthcare Stocks ↗
The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That May Collapse This Quarter ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
News headline image
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Jabil Posts Upbeat Earnings, Joins Micron Technology, Southwest Airlines And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Down Over 2%; US Initial Jobless Claims Fall ↗
 
Via Benzinga
News headline image
A Biotech Breakout Will Be Led By Small Caps ↗
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever. 
Via Talk Markets
Topics Artificial Intelligence Economy
News headline image
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
3 Precision Medicine Stocks Tailoring Treatments ↗
With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider. 
Via InvestorPlace
News headline image
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Mighty Mites: 3 Small-Cap Stocks Packing a Powerful Punch ↗
While small-cap stocks to buy present a higher-risk profile, these ideas may also pack considerable punch for their size. 
Via InvestorPlace
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
News headline image
Why Adaptive Biotechnologies Topped the Market Today ↗
A double beat on earnings, plus positive adjustments to certain guidance items, lifted the company's shares. 
Via The Motley Fool
News headline image
ADPT Stock Earnings: Adaptive Biotechnologies Beats EPS, Beats Revenue for Q1 2024 ↗
ADPT stock results show that Adaptive Biotechnologies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.